Black Diamond Therapeutics (NASDAQ:BDTX) Price Target Increased to $15.00 by Analysts at Piper Sandler

Black Diamond Therapeutics (NASDAQ:BDTX) had its price objective raised by Piper Sandler from $12.00 to $15.00 in a research report sent to investors on Monday morning, Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts have also recently weighed in on BDTX. Wedbush reaffirmed an outperform rating and set a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, September 10th. HC Wainwright restated a buy rating and issued a $11.00 target price on shares of Black Diamond Therapeutics in a report on Wednesday, September 18th. Finally, Raymond James assumed coverage on shares of Black Diamond Therapeutics in a report on Wednesday, July 31st. They issued an outperform rating and a $20.00 target price for the company.

Black Diamond Therapeutics Stock Down 5.5 %

Shares of Black Diamond Therapeutics stock opened at $4.50 on Monday. The company has a market cap of $253.14 million, a price-to-earnings ratio of -2.71 and a beta of 2.49. The company’s 50 day moving average is $5.66 and its 200 day moving average is $5.36. Black Diamond Therapeutics has a twelve month low of $1.62 and a twelve month high of $7.66.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its earnings results on Tuesday, August 6th. The company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.03. Sell-side analysts expect that Black Diamond Therapeutics will post -1.4 EPS for the current fiscal year.

Institutional Trading of Black Diamond Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Susquehanna Fundamental Investments LLC purchased a new stake in Black Diamond Therapeutics in the 1st quarter worth $82,000. SG Americas Securities LLC acquired a new position in Black Diamond Therapeutics in the second quarter valued at about $108,000. Jump Financial LLC lifted its position in Black Diamond Therapeutics by 245.0% in the fourth quarter. Jump Financial LLC now owns 38,888 shares of the company’s stock valued at $109,000 after buying an additional 27,616 shares during the last quarter. Algert Global LLC acquired a new position in Black Diamond Therapeutics in the second quarter valued at about $133,000. Finally, Pale Fire Capital SE acquired a new stake in shares of Black Diamond Therapeutics during the fourth quarter worth about $144,000. 95.47% of the stock is currently owned by institutional investors and hedge funds.

Black Diamond Therapeutics Company Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.